Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 GP-2250’s antineoplastic effects on ovarian cancer cells...